-
Avidity Biosciences Sets Record Date for Potential Spin-Off of RNA Therapeutics Business
NASDAQ: $RNA Avidity Biosciences, Inc. has recently announced a significant corporate development concerning its RNA therapeutics business. The company has established an expected record date for the potential separation of its RNA therapeutics business into an independent, publicly traded entity. The Potential Spin-Off Explained In a move designed to potentially maximize shareholder value and allow…
-
ADC Therapeutics Strengthens Team with New Employee Inducement Grants
NYSE: $ADCT ADC Therapeutics SA, a commercial-stage, late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from cancer, recently announced a significant commitment to its growing workforce. In a filing dated December 17, 2024, the company disclosed the granting of equity awards to newly hired employees under…
-
Anixa Biosciences Advances CAR-T Therapy with U.S. Adopted Name Approval
NASDAQ: $ANIX Anixa Biosciences, Inc., a biotechnology company focused on the development of innovative cancer therapies, has reached a significant milestone in the progression of its CAR-T cell therapy candidate. The company announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name for its novel CAR-T therapy. This approval of a…
-
Edgewise Therapeutics Announces Inducement Grants Under Nasdaq Rules
NASDAQ: $EWTX Edgewise Therapeutics Reports Inducement Grants as Permitted by Nasdaq Listing Rules Edgewise Therapeutics, Inc., a company focused on developing transformative therapies for muscular dystrophies, has recently announced the issuance of new equity awards. These grants were made as inducement awards to newly hired non-executive employees, a practice fully compliant with the Nasdaq Stock…
-
SBC Medical Supported Nasukai and Daibi Medical Aesthetics Forge Strategic Alliance to Enhance Patient Care
NASDAQ: $SBC SBC Medical Supported Medical Corporation Nasukai, a prominent entity in the medical sector, today announced the formation of a significant strategic alliance with Daibi Medical Aesthetics. This collaboration marks a pivotal moment for both organizations, signaling a commitment to expanding high-quality medical services and enhancing patient experience across their respective domains. SBC is…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-01-2026 TO 02-07-2026
The Groundhog sees his shadow, so hunker down and trade more to warm up! 😉 We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions…
$AMGN, $AZN, $BMY, $BSX, $DNLI, $GKOS, $GSK, $INCY, $JAZZ, $LLY, $MRNA, $PHVS, $REGN, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases -
Hoth Therapeutics Reports Significant Initial Results in Novel Cancer Therapy Trial
NASDAQ: $HOTH A recent press release from PR Newswire highlights exciting early data from Hoth Therapeutics regarding their ongoing clinical study involving a novel treatment approach for cancer patients whose tumors express the Epidermal Growth Factor Receptor (EGFR). The announcement, specifically concerning the open-label pharmacokinetic (PK) cohort of the study, signals a promising step forward…
-
SweetWater Brewing Announces ‘Big Trip’ Double IPA: A Bold New Flavor for Craft Beer Enthusiasts
NASDAQ: $TLRY Craft beer aficionados, get ready to mark your calendars! SweetWater Brewing Company, known for its distinctive style and commitment to quality brewing, has just announced the arrival of a highly anticipated new addition to its lineup: the Big Trip Double IPA. This news, officially released via a press statement on January 22, 2026,…
-
PDS Biotech Secures New U.S. Patent for Core Technology
NASDAQ: $PDSB Pharmaceutical development is a meticulous and often lengthy process, where intellectual property protection is paramount to innovation. In a significant move for the sector, PDS Biotech recently announced the issuance of a new U.S. Patent. This patent specifically covers the fundamental technology platform that underpins one of the company’s key investigational products, PDS0.…